Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 in stable schizophrenia
NCT02418819Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of razpipadon in schizophrenia (4 arms), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events, Vital Signs Abnormalities and 5 more. Started Apr 2015; status: completed.
02
Drugs
razpipadon
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02418819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418819.